Teleflex Completes Enrollment in Longer-Length Freesolve Scaffold Study
Event summary
- Teleflex completed enrollment in the BIOMAG™-LL Clinical Study evaluating 35 mm and 40 mm Freesolve™ Resorbable Magnesium Scaffolds for coronary lesions up to 38 mm.
- The study is a premarket, prospective, international, multi-center, single-arm trial with a primary endpoint of Target Lesion Failure (TLF) rate at 12 months.
- Clinical follow-up is scheduled at 1, 6, 12, 36, and 60 months post-procedure.
- The study aims to expand treatment options for long coronary lesions, reducing the need for permanent implants.
The big picture
Teleflex's completion of the BIOMAG™-LL Clinical Study is a strategic move to address the challenge of long coronary lesions in percutaneous coronary intervention (PCI). The study's success could position Teleflex as a leader in resorbable scaffold technology, offering an alternative to permanent implants and drug-coated balloons. This aligns with the broader industry trend towards minimally invasive and temporary solutions in interventional cardiology.
What we're watching
- Clinical Efficacy
- Whether the longer Freesolve™ Scaffolds demonstrate superior safety and effectiveness in treating longer coronary lesions compared to existing options.
- Regulatory Approval
- The pace at which Teleflex can secure regulatory approvals for the longer scaffold lengths, particularly in key markets.
- Market Adoption
- How quickly physicians adopt the longer scaffold lengths once data is available, and whether this expands Teleflex's market share in resorbable scaffold technology.
Related topics
